uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Dalteparin: over 20 years of clinical experience
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Surgical Sciences.
2008 (English)In: EJHP Practice, ISSN 1781-9989, Vol. 14, no 2, 38-44 p.Article in journal (Refereed) Published
Abstract [en]

Dalteparin was one of the first low molecular weight heparins (LMWHs) to be used in clinical practice, and was initially available for the prevention of venous thromboembolic disease and for haemodialysis. In more than two decades of clinical use, extensive clinical studies have evaluated the role of dalteparin in a wide range of therapeutic areas. These include: the prevention of venous thromboembolism (VTE) in surgical patients (general surgery, surgery for abdominal/pelvic cancers, high-risk orthopaedic surgery) and in acutely ill medical patients; the prevention of recurrent VTE in patients with cancer; and the management of acute coronary syndromes (ACS). This article provides an update on the range of clinical indications for dalteparin, and the findings of relevant clinical trials.

Place, publisher, year, edition, pages
2008. Vol. 14, no 2, 38-44 p.
Keyword [en]
dalteparin, heparin, low molecular weight heparin (LMWH), thromboprophylaxis
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-152204ISI: 000259638600021OAI: oai:DiVA.org:uu-152204DiVA: diva2:412975
Available from: 2011-04-27 Created: 2011-04-27 Last updated: 2011-04-27Bibliographically approved

Open Access in DiVA

No full text

By organisation
Department of Surgical Sciences
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 174 hits
ReferencesLink to record
Permanent link

Direct link